Wide Ranks

AQST

Aquestive Therapeutics, Inc.

5.16

Top Statistics
Market Cap 470 M Forward PE -9.60 Revenue Growth 4.20 %
Current Ratio 6.37 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins -59.75 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -21.43 Enterprise / Revenue 7.29 Price To Sales Trailing12 Months 7.99
Profitability
Profit Margins -59.75 % Operating Margins -61.22 %
Balance Sheet
Total Cash 77 M Total Cash Per Share 0.8540 Total Debt 36 M
Total Debt To Equity Current Ratio 6.37 Book Value Per Share -0.4980
All Measures
Short Ratio 612.00 % Message Board Id finmb_8142504 Shares Short Prior Month 10 M
City Warren Uuid 22956725-87cb-39ad-9e8b-1bc1480b8337 Previous Close 4.88
First Trade Date Epoch Utc 1 B Book Value -0.4980 Beta 2.82
Total Debt 36 M Volume 1 M Fifty Two Week Low 1.84
Total Cash Per Share 0.8540 Total Revenue 58 M Shares Short Previous Month Date 1 B
Target Median Price 10.00 Audit Risk 8 Max Age 86400
Sand P52 Week Change 0.3133 Operating Margins -61.22 % Target Mean Price 10.06
Net Income To Common -35193000 Short Percent Of Float 0.1309 Implied Shares Outstanding 91 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 1 M
Average Volume10days 1 M Total Cash 77 M Next Fiscal Year End 1 B
Revenue Per Share 0.7300 Held Percent Insiders 0.0501 Ebitda Margins -34.02 %
Trailing PE 0.0000 Date Short Interest 1 B Most Recent Quarter 1 B
Share Holder Rights Risk 8 Regular Market Previous Close 4.88 Target Low Price 5.50
Gmt Off Set Milliseconds -18000000 Fifty Day Average 4.99 Open 4.94
Free Cashflow -12320875 State NJ Dividend Yield 0.00 %
Return On Assets -0.1557 Time Zone Short Name EST Board Risk 6
Trailing Eps -0.4500 Day Low 4.90 Address1 30 Technology Drive
Shares Outstanding 91 M Compensation Risk 6 Price Hint 2
Target High Price 15.00 Website https://www.aquestive.com 52 Week Change 1.29
Average Volume 1 M Forward Eps -0.6000 Recommendation Key none
Compensation As Of Epoch Date 1 B Quick Ratio 578.00 % Is_sp_500 False
Regular Market Day High 5.20 Profit Margins -59.75 % Fifty Two Week High 6.23
Day High 5.20 Shares Short 9 M Regular Market Open 4.94
Industry Key drug-manufacturers-specialty-generic Earnings Growth 0.00 % Enterprise To Revenue 7.29
Revenue Growth 4.20 % Shares Percent Shares Out 0.1093 Operating Cashflow -34212000
Currency USD Time Zone Full Name America/New_York Market Cap 470 M
Is_nasdaq_100 False Zip 07059 Quote Type EQUITY
Industry Drug Manufacturers - Specialty & Generic Long Name Aquestive Therapeutics, Inc. Overall Risk 6
Regular Market Day Low 4.90 Held Percent Institutions 0.5536 Current Price 5.16
Enterprise To Ebitda -21.43 Financial Currency USD Current Ratio 6.37
Gross Margins 69.39 % Industry Disp Drug Manufacturers - Specialty & Generic Number Of Analyst Opinions 8
Country United States Float Shares 80 M Two Hundred Day Average 3.98
Governance Epoch Date 1 B Enterprise Value 429 M Price To Sales Trailing12 Months 7.99
Forward PE -9.60 Regular Market Volume 1 M Ebitda -20038000
Exchange NGM
Go to Yahoo Finance Go to Seeking Alpha 
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally.

The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.

Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis.

The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis.

In addition, it develops Adrenaverse, an epinephrine prodrug platform.

The company was incorporated in 2004 and is headquartered in Warren, New Jersey.